Myomo Taps Inspire Vet Katie McClure as CCO to Scale Bionic Arm Tech

BURLINGTON, Mass. – October 12, 2026 – In the medical technology sector, there is a well-documented chasm between proving a device works and proving it can sustain a profitable, nationwide business. Myomo, Inc., the Burlington-based wearable medical robotics company, has spent the last decade crossing the first half of that divide. Now, with the appointment of Mary-Katherine "Katie" McClure as Chief Commercial Officer, effective today, the company is signaling its intent to conquer the second.

McClure steps into the role succeeding Micah Mitchell, who will remain with the company through December 23, 2026, to ensure a seamless transition. The executive swap is not a rescue mission; rather, it is a strategic hand-off at a critical pivot point. Under Mitchell’s tenure, Myomo evolved from a niche rehabilitation player generating less than $2 million in annual revenue to a commercial enterprise exceeding $40 million. More importantly, Mitchell engineered the company’s direct provider business, an infrastructure that now accounts for approximately 70% of Myomo's annual revenues.

But scaling from $40 million to the hundreds of millions requires a distinctly different operational playbook—one that McClure has executed with remarkable precision before.

The Inspire Playbook and the $150 Million Blueprint

The recruitment of McClure is a calculated maneuver by Myomo’s board, drawing directly from one of the most successful medtech growth stories of the past decade. McClure arrives from Inspire Medical Systems, a company that revolutionized the treatment of sleep apnea with an implantable neurostimulation device. During her tenure, which began in 2018, Inspire’s total revenues skyrocketed from roughly $50 million to nearly $1 billion.

More relevant to Myomo’s immediate future is McClure’s specific regional impact at Inspire. In the territories under her direct leadership, revenues expanded from $2 million to $150 million. That hyper-growth was not achieved through simple salesmanship; it required the systematic dismantling of market barriers, the alignment of clinical networks, and the relentless pursuit of physician engagement.

"Her experience building commercial teams, expanding market access, and scaling clinical networks is directly relevant to our strategic plan," said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo.

For Myomo, the parallels are striking. The company’s flagship product, the MyoPro, is currently the only marketed device in the United States that uses non-invasive electromyographic (EMG) sensors to read a patient’s own neurological signals, effectively restoring function to arms paralyzed or weakened by stroke, brachial plexus injuries, or spinal cord trauma. Like Inspire’s sleep apnea device, the MyoPro is a paradigm-shifting technology that requires a complex ecosystem of orthotics and prosthetics (O&P) providers, physical therapists, and referring physicians to achieve mainstream adoption.

McClure’s mandate is to build that ecosystem on a national scale. As she noted upon her appointment, the goal is to construct a "sustainable nationwide eco-system" that normalizes the prescription and fitting of the MyoPro.

The Inducement: Betting on the 2029 Horizon

The financial architecture of McClure’s compensation package underscores the sheer scale of Myomo’s ambitions. In reliance on the employment inducement exception under Section 711 of the NYSE American Company Guide, McClure was granted a substantial equity package designed to align her financial outcomes with aggressive corporate growth.

The package includes a time-based award of 275,000 restricted stock units (RSUs) vesting over three years. However, the true indicator of the board's expectations lies in the performance-based equity award. McClure was granted 225,000 performance-based RSUs at target, with the potential to earn up to 337,500 shares based on specific 2029 metrics.

Half of this performance award is tethered to the achievement of stringent financial targets for the year ending December 31, 2029. The other half is tied to Myomo’s stock price performance in the fourth quarter of 2029 relative to a peer group, compared to its baseline in the fourth quarter of 2026. This structure effectively locks the new commercial chief into a three-year sprint, demanding not just localized sales growth, but holistic, market-beating enterprise value creation.

The Market Access Battle: Navigating the Medicare Moat

To hit those 2029 targets, McClure will need to master the most complex variable in the American healthcare system: reimbursement. The underlying engine of Myomo’s recent revenue acceleration—including its $11.7 million second-quarter performance in 2026, representing a 21% year-over-year increase—has been its evolving relationship with third-party payers.

The watershed moment for Myomo arrived in April 2024, when the Centers for Medicare & Medicaid Services (CMS) began reimbursing the MyoPro under Medicare Part B. By classifying the custom-fabricated device within the brace category of durable medical equipment and reimbursing it on a lump-sum basis, CMS unlocked access for an estimated 50% of seniors with standard fee-for-service Medicare.

The impact of this regulatory victory cannot be overstated. By early 2026, Medicare Part B patients represented over half of Myomo’s quarterly revenue. While the Veterans Administration and various commercial insurers have reimbursed the device for years, the CMS decision provided the volume necessary to transition Myomo from a cash-burning startup to a company approaching financial sustainability. In fact, by the end of 2024, the company had achieved its first quarter of positive Adjusted EBITDA, and its operating cash burn has continued to shrink significantly into 2026.

However, heavy reliance on a single payer channel presents a structural vulnerability. Industry analysts frequently point to revenue concentration with Medicare Part B as a primary risk factor for the company. Any shifts in CMS coding, coverage determinations, or supply chain disruptions that delay custom fittings could immediately choke the company’s cash flow.

McClure’s background at Medtronic, Tobii Dynavox, and Johnson & Johnson equips her for this exact battlefield. Her task will be to defend the Medicare Part B beachhead while aggressively expanding in-network payer access across commercial lines. Myomo has already made strides here, securing contracts with state Elevance Anthem Blue Cross Blue Shield networks covering millions of lives. The new CCO must now accelerate this commercial contracting, transforming regional coverage wins into a ubiquitous national standard.

Transitioning Beyond the Founder-Led Era

The departure of Micah Mitchell marks the end of an era for Myomo. Building a direct-to-patient and direct-provider business model from scratch is notoriously difficult in the orthotics space, which is traditionally dominated by fragmented, independent clinics. Mitchell successfully centralized that process, proving that a medical robotics company could control its own commercial destiny.

"Micah was instrumental in building our commercial organization to support the creation of our direct provider business," Gudonis acknowledged, praising the outgoing executive for laying the foundation that now generates the lion's share of the company's capital.

As Mitchell prepares to exit in late December, the spotlight shifts entirely to McClure. The wearable medical robotics market is no longer a futuristic concept; it is an active clinical reality. With a proven product, established Medicare reimbursement, and a growing pipeline of international expansion—particularly in Germany and through joint ventures in China—Myomo possesses the raw materials for massive scale. The challenge now is execution. By importing the commercial playbook that turned sleep apnea neurostimulation into a billion-dollar industry, Myomo is betting that its bionic arms are ready for the exact same trajectory.